Turnaround gains momentum as core mRNA business accelerates
- Q3 2026 mRNA revenue accelerated, growing 28% year over year.
- The company surpassed its full-year conversion target with 10 new GMP customers.
- The AI-powered mRNAbuilder platform now has over 180 active customers.
- Cygnus provided steady growth for a sixth consecutive quarter.
- Large manufacturing orders remain lumpy and can cause volatility.
A proven post-COVID turnaround
Maravai provided strong confirmation in Q3 2026 that its turnaround is real and accelerating. The core mRNA business grew 28% year over year, with discovery mRNA up 27% and GMP consumables surging 30%. Cygnus added steady growth, expanding 8%.
The restructuring plan implemented in 2025 continues to yield serious benefits. The leaner cost structure drove over 1,700 basis points of margin expansion in Q3. The company is also successfully executing its land and expand strategy, surpassing its full-year target by converting 10 customers from research to GMP year to date.
The bear case now centers on the timing of large orders rather than structural decline. Contract manufacturing and large GMP orders are program driven, making quarterly revenue vulnerable to shifts if a customer delays a clinical trial. Major commercial scale up for the current pipeline is not expected until 2028 or 2029.
Finn views the situation as materially improved. The AI-powered mRNAbuilder platform is seeing strong adoption with over 180 active customers. The main question going forward is whether the high growth rates in early discovery mRNA can be maintained until those programs reach the clinic.
Tools for drug makers
Maravai sells products used by drug, vaccine, diagnostic, and research customers. The business relies on a land and expand strategy. It seeds future manufacturing demand by winning customers early in their discovery phases, hoping to retain them as they move into commercial production.
Its TriLink unit makes modified nucleic acids, including CleanCap analogs and GMP mRNA. These are building blocks and process inputs for advanced therapy work. Cygnus sells products and services that help biologic drug makers test for impurities, which is critical for drug safety.
Sales are increasingly driven by a highly successful e-commerce platform and AI tools. The proprietary mRNAbuilder expands the company's role from a reagent supplier to a design service provider. This creates a new channel for acquiring early-stage customers.
The company executed a 2025 Corporate Realignment Plan to cut costs. This plan is now flowing through the income statement, providing operating leverage and significantly expanding margins as revenue recovers.
What Maravai sells
mRNA products
This is the largest piece of TriLink. It includes CleanCap analogs used in mRNA vaccine and therapy production, and saw 28% growth in Q3 2026.
GMP consumables
TriLink makes highly modified nucleic acids and GMP mRNA for customers moving into higher-grade clinical production. This segment grew 30% in Q3 2026.
Specialty Chemistry
Making up roughly 20% of revenue, this category includes discovery consumables and highly specialized chemical inputs for research.
CDMO services
Contract manufacturing represents less than 5% of revenue but serves as a strategic capability for customers scaling up their therapies.
GMP-grade enzymes
A newly launched portfolio designed to expand single-source capabilities for customers. The company expects to add GMP-grade ModTail before the end of 2026.
Cygnus impurity testing
Cygnus provides antibody-based products and services that detect impurities in biologic drug manufacturing. It provides stable, recurring, high-margin revenue.
Q1 mix favors TriLink
Segment mix is from the three months ended March 31, 2026. TriLink was about 72.1% of revenue, and Q3 2026 confirmed this core segment is now growing rapidly with mRNA revenue up 28%.
What could still break
Lumpy manufacturing orders
High impact · High oddsThe CDMO and large GMP orders are inherently lumpy. They depend on specific customer clinical programs. A delay in just one or two customer trials can shift revenue out of a quarter and cause unexpected misses.
Delayed clinical scaling
Medium impact · Medium oddsCommercial programs from the current clinical pipeline are not expected to scale into large revenue drivers until 2028 or 2029. Until then, near-term growth relies heavily on discovery and early clinical phases.
Biotech funding constraints
Medium impact · Medium oddsMaravai sells into drug discovery and development markets. If early-stage biotech customers face tight R&D budgets, demand for early discovery products could weaken again.
Impairment history
High impact · Low oddsMaravai recorded massive goodwill and intangible asset impairments in 2025. While operations are improving, any return to weak demand could trigger further write-downs of remaining assets.
In one breath
What does Maravai LifeSciences do?
Maravai sells life science tools used to develop drugs, vaccines, diagnostics, and biologics. Its biggest unit, TriLink, focuses on mRNA and nucleic acid products, while Cygnus focuses on biologics safety testing.
Is Maravai growing again?
Yes. After a long decline, the company reported 28% growth in its core mRNA revenue during Q3 2026. Cygnus also grew 8% year over year.
What is the biggest risk for MRVI stock?
The biggest risk is the lumpy nature of large commercial manufacturing orders. Because a few large programs drive significant revenue, changes in customer timelines can cause revenue to swing unpredictably from quarter to quarter.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Maravai LifeSciences Holdings, Inc. in Finn's Biotechnology industry ranking.

